Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.79 is in line with its 5-year average of -3.47, near the low end of its 5-year range (-6.50–3.01).
9.22% above its 12-month average of -4.17.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.43.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 31 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:23:22.927Z. Historical observations retain their original dates. Historical series through 2023-02-28.
EARNINGS PER SHARE (EPS)
-3.79
EARNINGS PER SHARE (EPS) AVG TTM
-4.17
EARNINGS PER SHARE (EPS) AVG 3Y
-5.22
EARNINGS PER SHARE (EPS) AVG 5Y
-3.47
EARNINGS PER SHARE (EPS) AVG 10Y
-2.55
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+9.22%
CURRENT VS 3Y AVG
+27.36%
CURRENT VS 5Y AVG
-9.12%
CURRENT VS 10Y AVG
-48.84%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
REGENXBIO Inc.
Market Cap
$387.73M
Earnings Per Share (EPS)
-3.79
TTM Avg
-4.17
3Y Avg
-5.22
5Y Avg
-3.47
Market Cap
$385.22M
Earnings Per Share (EPS)
-1.54
TTM Avg
-2.79
3Y Avg
-2.67
5Y Avg
-2.08
Market Cap
$391.80M
Earnings Per Share (EPS)
-5.18
TTM Avg
-2.77
3Y Avg
-1.90
5Y Avg
-1.90
Market Cap
$382.49M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.34
3Y Avg
-0.07
5Y Avg
0.03
Market Cap
$381.14M
Earnings Per Share (EPS)
-2.94
TTM Avg
-3.49
3Y Avg
-2.70
5Y Avg
-2.28
Market Cap
$376.61M
Earnings Per Share (EPS)
-3.33
TTM Avg
-2.70
3Y Avg
-1.54
5Y Avg
-2.91
Market Cap
$373.99M
Earnings Per Share (EPS)
-0.50
TTM Avg
-5.17
3Y Avg
-17.19
5Y Avg
-12.52
Market Cap
$403.87M
Earnings Per Share (EPS)
-4.63
TTM Avg
-6.16
3Y Avg
-6.16
5Y Avg
-6.16
Market Cap
$406.04M
Earnings Per Share (EPS)
-5.51
TTM Avg
-4.26
3Y Avg
-3.91
5Y Avg
-2.87
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| REGENXBIO Inc. (RGNX) | $387.73M | -3.79 | -4.17 | -5.22 | -3.47 |
| Orthofix Medical Inc. (OFIX)vs › | $385.22M | -1.54 | -2.79 | -2.67 | -2.08 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $391.80M | -5.18 | -2.77 | -1.90 | -1.90 |
| YD Bio Limited Ordinary Shares (YDES)vs › | $382.49M | N/A | -0.34 | -0.07 | 0.03 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $381.14M | -2.94 | -3.49 | -2.70 | -2.28 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $376.61M | -3.33 | -2.70 | -1.54 | -2.91 |
| Canopy Growth Corporation (CGC)vs › | $373.99M | -0.50 | -5.17 | -17.19 | -12.52 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $403.87M | -4.63 | -6.16 | -6.16 | -6.16 |
| Neurogene Inc. (NGNE)vs › | $406.04M | -5.51 | -4.26 | -3.91 | -2.87 |
| Carlsmed, Inc. (CARL)vs › | $406.41M | -1.36 | -1.81 | -2.62 | -2.62 |
Trailing EPS (TTM)
$-3.79
Forward EPS (Est.)
$-3.36
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.76 |
| 2024-12-31 | -4.59 |
| 2023-12-31 | -6.02 |
| 2022-12-31 | -6.50 |
| 2021-12-31 | 3.01 |
| 2020-12-31 | -2.98 |
| 2019-12-31 | -2.58 |
| 2018-12-31 | 2.73 |
| 2017-12-31 | -2.45 |
| 2016-12-31 | -2.38 |
| 2015-12-31 | -2.49 |
| 2014-12-31 | -0.30 |
| 2013-12-31 | -2.04 |
